176 related articles for article (PubMed ID: 24510766)
1. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
2. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
3. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
4. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
Marty MS; O'Connor JC
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
[TBL] [Abstract][Full Text] [Related]
5. Scientific and Regulatory Policy Committee (SRPC) Points to Consider: Histopathology Evaluation of the Pubertal Development and Thyroid Function Assay (OPPTS 890.1450, OPPTS 890.1500) in Rats to Screen for Endocrine Disruptors.
Keane KA; Parker GA; Regan KS; Picut C; Dixon D; Creasy D; Giri D; Hukkanen RR
Toxicol Pathol; 2015 Dec; 43(8):1047-63. PubMed ID: 25948506
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ammonium perchlorate in the endocrine disruptor screening and testing program's male pubertal protocol: ability to detect effects on thyroid endpoints.
Stoker TE; Ferrell JM; Laws SC; Cooper RL; Buckalew A
Toxicology; 2006 Nov; 228(1):58-65. PubMed ID: 17011691
[TBL] [Abstract][Full Text] [Related]
8. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
9. Assessment of DE-71, a commercial polybrominated diphenyl ether (PBDE) mixture, in the EDSP male and female pubertal protocols.
Stoker TE; Laws SC; Crofton KM; Hedge JM; Ferrell JM; Cooper RL
Toxicol Sci; 2004 Mar; 78(1):144-55. PubMed ID: 14999130
[TBL] [Abstract][Full Text] [Related]
10. Analysis of EPA's endocrine screening battery and recommendations for further review.
Schapaugh AW; McFadden LG; Zorrilla LM; Geter DR; Stuchal LD; Sunger N; Borgert CJ
Regul Toxicol Pharmacol; 2015 Aug; 72(3):552-61. PubMed ID: 26044367
[TBL] [Abstract][Full Text] [Related]
11. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
Borgert CJ
Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
[TBL] [Abstract][Full Text] [Related]
12. Effects of altered food intake during pubertal development in male and female wistar rats.
Laws SC; Stoker TE; Ferrell JM; Hotchkiss MG; Cooper RL
Toxicol Sci; 2007 Nov; 100(1):194-202. PubMed ID: 17728285
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
[TBL] [Abstract][Full Text] [Related]
14. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
[TBL] [Abstract][Full Text] [Related]
15. Introduction to "screening for endocrine activity-experiences with the US EPA's endocrine disruptor screening program and future considerations".
Marty S
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):1-2. PubMed ID: 24510782
[No Abstract] [Full Text] [Related]
16. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
17. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
18. Histologic features of prepubertal and pubertal reproductive development in female Sprague-Dawley rats.
Picut CA; Remick AK; Asakawa MG; Simons ML; Parker GA
Toxicol Pathol; 2014; 42(2):403-13. PubMed ID: 23599412
[TBL] [Abstract][Full Text] [Related]
19. Effect of feed restriction on Hershberger and pubertal male assay endpoints.
Marty MS; Johnson KA; Carney EW
Birth Defects Res B Dev Reprod Toxicol; 2003 Aug; 68(4):363-74. PubMed ID: 14666999
[TBL] [Abstract][Full Text] [Related]
20. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
